Linatab 5

Indications

Linatab is prescribed for adults with type 2 diabetes mellitus to enhance glycemic control.

• As Monotherapy: For patients whose diabetes is inadequately managed through diet and exercise alone, and who cannot tolerate metformin or have renal impairment.
• As Combination Therapy: To be used alongside metformin when diet and exercise, combined with metformin, fail to achieve sufficient glycemic control; also in combination with a sulfonylurea and metformin when dual therapy does not suffice.

Consult a registered healthcare professional before using this medication.

Pharmacology

Linagliptin, a DPP-4 (dipeptidyl peptidase-4) inhibitor, improves glycemic control by increasing levels of active incretin hormones. This action stimulates insulin release from pancreatic beta (β) cells in a glucose-dependent manner while reducing glucagon secretion from pancreatic alpha (α) cells.

Dosage & Administration

The standard dosage of Linagliptin is 5 mg once daily. If combined with metformin, continue the metformin dosage while adding Linagliptin. In cases where Linagliptin is used with a sulfonylurea, a lower sulfonylurea dose may be necessary to minimize hypoglycemia risk.

Note: No dose adjustment is required for patients with renal impairment. Linagliptin can be taken with or without food at any time during the day.

Consult a registered healthcare professional before using this medication.

Interaction

Linatab is a weak competitive inhibitor of the CYP3A4 isozyme, but has low potential for significant interactions with other medications. In clinical trials, it did not adversely affect the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin, or oral contraceptives.

Contraindications

Linatab should not be used by individuals with known hypersensitivity to Linagliptin or any of its components.

Side Effects

Common side effects may include hypoglycemia, nasopharyngitis, cough, and pancreatitis when combined with metformin or sulfonylurea.

Pregnancy & Lactation

Linatab is classified as Pregnancy Category B. Due to a lack of adequate studies, it should only be used during pregnancy if the benefits clearly outweigh the risks. The transfer of Linagliptin into breast milk is not well established.

Precautions & Warnings

Exercise caution in patients with hypersensitivity to Linagliptin or its excipients.

Therapeutic Class

Dipeptidyl Peptidase-4 (DPP-4) Inhibitor

Storage Conditions

Store Linatab in a cool, dry place, away from light and heat, and out of reach of children.